Publications

View list publications or conduct a pubmed search.

 

2022

Kanao R, Kawai H, Taniguchi T, Takata M, Masutani C (2022). RFWD3 and translesion DNA polymerases contribute to PCNA modification-dependent DNA damage tolerance. Life Sci Alliance, 5 (12), e202201584.

 

2019

Taniguchi T (2019). REV1-POL ζ Inhibition and Cancer Therapy. Mol Cell, 75(3): 419-420.

Hu WF, Krieger KL, Lagundžin D, Li X, Cheung RS, Taniguchi T, Johnson KR, Bessho T, Monteiro ANA, Woods NT (2019). CTDP1 Regulates Breast Cancer Survival and DNA Repair Through BRCT-specific Interactions With FANCI. Cell Death Discov, 5, 105.

2017

Cheung RS and Taniguchi T (2017). Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers. Int J Hematol, 106(3), 335-44.

Cheung RS, Castella M, Abeyta A, Gafken PR, Tucker N and Taniguchi T (2017). Ubiquitination-Linked Phosphorylation of the FANCI S/TQ Cluster Contributes to Activation of the Fanconi Anemia I/D2 Complex. Cell Rep, 19(12): 2432-40.

Calses PC, Dhillon KK, Tucker N, Chi Y, Huang JW, Kawasumi M, Nghiem P, Wang Y, Clurman BE, Jacquemont C, Gafken PR, Sugasawa K, Saijo M and Taniguchi T (2017). DGCR8 Mediates Repair of UV-Induced DNA Damage Independently of RNA Processing. Cell Rep, 19(1): 162-74.

Abeyta A, Castella M, Jacquemont C and Taniguchi T (2017). NEK8 regulates DNA damage-induced RAD51 foci formation and replication fork protection. Cell Cycle, 16(4): 335-47.

 

2016

Dhillon KK, Bajrami I, Taniguchi T and Lord CJ (2016). Synthetic lethality: the road to novel therapies for breast cancer. Endcr Relat Cancer, 23(10): T39-55.

Drost R, Dhillon KK, van der Gulden H, van der Heiden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P and Jonkers J (2016). BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest, 126(8): 2903-18.

Chen DH, Below JE, Shimamura A, Keel SB, Matsushita M, Wolff J, Sul Y, Bonkowski E, Castella M, Taniguchi T, Nickerson D, Papayannopoulou T, Bird TD and Raskind WH (2016). Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L. Am J Hum Genet, 98(6): 1146-58.

 

2015

Castella M, Jacquemont C, Thompson EL, Yeo JE, Cheoung RS, Huang JW, Sobeck A, Hendrickson EA and Taniguchi T (2015). FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2. PLoS Genet, 11(10): e1005563.

 

2014

Wang Y, Huang JW, Castella M, Huntsman DG and Taniguchi T (2014). p53 is positively regulated by miR-524-3p. Cancer Res, 74(12): 3218-27.

 

2013

Huang JW, Wang Y, Dhillon KK, Calses P, Villegas E, Mitchell PS, Tewari M, Kemp CJ and Taniguchi T (2013). Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res, 11(12): 1564-73.

Pennington KP, Wickramanayake A, Norquist BM, Kaufmann SH, Pennil CC, Garcia RL, Agnew KJ, Halzonetis TD, Taniguchi T, Welcsh P, and Swisher EM (2013). 53BP1 expression in sporadic and inherited ovarian carcinoma: relationship to genetic status and clinical outcomes. Gynecologic Oncology, 128(3): 493-9.

Wang Y and Taniguchi T (2013). MicroRNAs and DNA damage response: implication in cancer therapy. (review) Cell Cycle, 12(1): 32-42.

 

2012

Wang Y, Huang JW, Calses P, Kemp CJ, and Taniguchi (2012). MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibitor. Cancer Research, 72(16): 4037-46.

Jacquemont C, Simon, JA, D’Andrea, AD, and Taniguchi T (2012) Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Molecular Cancer, 11:26.

Swisher EM, Taniguchi T, and Karlan BY (2012) Molecular Scores to Predict Ovarian Cancer Outcomes: A Worthy Goal, but Not Ready for Prime Time. J Natl Cancer Inst., 104(9): 642-5.

 

2011

Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, Tewari M, Furnari FB, Taniguchi T (2011) MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res., 9 (8), 1100-11.

Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM. (2011) Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol.,29 (22), 3008-15.

 

2010

Castella M, Taniguchi T (2010) The role of FAN1 nuclease in the Fanconi anemia pathway. (Commentary), Cell Cycle, 9 (21), 4259-60

Konstantinopoulos PA, Spentzos D, Karlan, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA (2010) Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer., J Clin Oncol, 28, 3555-3561

Dhillon KK, Swisher EM, Taniguchi T (2010) Secondary mutations of BRCA1/2 and drug resistance. (review), Cancer Science, 102, 663-669.

 

2009

Toshiyasu Taniguchi (2009) The Fanconi anemia-BRCA pathway and cancer, The DNA Damage Response: Implications on Cancer Formation and Treatment, Springer, ISBN=9789048125609 (bookchapter)

Wataru Sakai, Elizabeth M. Swisher, Céline Jacquemont, Kurapaty Venkatapoorna Chandramohan, Fergus J. Couch, Simon P. Langdon, Kaitlyn Wurz, Jake Higgins, Emily Villegas, Toshiyasu Taniguchi. (2009) Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma., Cancer Research, 69 (16), 6381-6

Elizabeth M. Swisher, Rachel Gonzales-Hernandez, Toshiyasu Taniguchi, Rochelle L. Garcia, Tom Walsh, Boxin Zhang, Melissa Wollan, Julia Willner, Barbara A. Goff, Piri Welcsh. (2009) Methylation and protein expression of DNA repair genes: Association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas., Molecular Cancer, 8 (1), 48

 

2008

Elizabeth M. Swisher, Wataru Sakai, Beth Y. Karlan, Kaitlyn Wurz, Nicole Urban, Toshiyasu Taniguchi (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance., Cancer Research, 68 (8), 2581-2586

Wataru Sakai, Elizabeth M. Swisher, Beth Y. Karlan, Mukesh K. Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J. Farrugia, Fergus J. Couch, Nicole Urban & Toshiyasu Taniguchi (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers, Nature, 451 (7182), 1116-1120

 

2007

Céline Jacquemont, Toshiyasu Taniguchi (2007) Proteasome function is required for DNA damage response and Fanconi anemia pathway activation, Cancer Research, 67 (15), 7395-7405

Toshiyasu Taniguchi, Fanconi Anemia, GeneReviews at GeneTests: Medical Genetics Information Resource [database online] Available at http://www.genetests.org, 2007

Clark C. Chen, Toshiyasu Taniguchi, Alan D’Andrea (2007) The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents, Journal of Molecular Medicine, 85 (5), 497-509

Céline Jacquemont, Toshiyasu Taniguchi (2007) The Fanconi anemia pathway and ubiquitin. (review), BMC Biochemistry, 8 (Suppl 1), S10

 

2006

Céline Jacquemont, Toshiyasu Taniguchi (2006) Disruption of the Fanconi anemia pathway in human cancer in the general population. (Commentary), Cancer Biology & Therapy, 5 (12), 1637-9

Gary P.H. Ho, Steven Margossian, Toshiyasu Taniguchi, Alan D. D’Andrea (2006) Phosphorylation of FANCD2 on Two Novel Sites is Required for MMC Resistance, Molecular and Cellular Biology, 26 (18), 7005-15

Taniguchi T, D’Andrea AD (2006) The Molecular Pathogenesis of Fanconi Anemia: Recent Progress (review), Blood, 107 (11), 4223-33

Mankad A, Taniguchi T, Cox B, et al. (2006) Natural gene therapy in monozygotic twins with Fanconi anemia, Blood, 107 (8), 3084-3090

Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D’Andrea AD. (2006) Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway, Mol Cancer Ther, 5 (4), 952-61

Toshiyasu Taniguchi (2006) Regulation of DNA repair by the ubiquitin system and its implication in cancer, AACR Education Book 2006, 166-170 pages (bookchapter)

Travis LB, Rabkin CS, Brown LM, et al. (2006) Cancer Survivorship – Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations (Commentary), Journal of the National Cancer Institute, 98 (1), 15-25

 

2005

Houghtaling S, Newell A, Akkari Y, Taniguchi T, Olson S, and Grompe M (2005) Fancd2 Functions in a Double Strand Break Repair Pathway That Is Distinct From Non-homologous End Joining, Human Molecular Genetics, 14 (20), 3027-33

Howlett NG, Taniguchi T, Durkin SG, D’Andrea AD, Glover TW (2005) The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability., Human Molecular Genetics, 14 (5), 693-701

Montes de Oca R, Andreassen PR, Margossian SP, Gregory RC, Taniguchi T, Wang X, Houghtaling S, Grompe M, D’Andrea AD (2005) Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin, Blood, 105 (3), 1003-9

Nakanishi K, Yang YG, Pierce AJ, Taniguchi T, Digweed M, D’Andrea AD, Wang ZQ, Jasin M (2005) Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair, Proceedings of the National Academy of Sciences of the United States of America, 102 (4), 1110-5

 

2004

Andreassen PR, D’Andrea AD, Taniguchi T (2004) ATR couples FANCD2 monoubiquitination to the DNA-damage response, Genes & Development, 18 (16), 1958-63

 

2003

Tischkowitz M, Ameziane N, Waisfisz Q, De Winter JP, Harris R, Taniguchi T, D’Andrea A, Hodgson SV, Mathew CG, Joenje H (2003) Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia, British Journal of Haematology, 123 (3), 469-71

Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D’Andrea AD (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors, Nature Medicine, 9 (5), 568-74

Gregory RC, Taniguchi T, D’Andrea AD (2003) Regulation of the Fanconi anemia pathway by monoubiquitination (review), Seminars in Cancer Biology, 13 (1), 77-82

 

2002

Nakanishi K, Taniguchi T, Ranganathan V, New HV, Moreau LA, Stotsky M, Mathew CG, Kastan MB, Weaver DT, D’Andrea AD (2002) Interaction of FANCD2 and NBS1 in the DNA damage response, Nature Cell Biology, 4 (12), 913-20

Adachi D, Oda T, Yagasaki H, Nakasato K, Taniguchi T, D’Andrea AD, Asano S, Yamashita T (2002) Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants, Human Molecular Genetics, 11 (25), 3125-34

Taniguchi T, D’Andrea AD (2002) The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC, Blood, 100 (7), 2457-62

Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D’Andrea AD (2002) S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51, Blood, 100 (7), 2414-20

Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D’Andrea AD (2002) Biallelic inactivation of BRCA2 in Fanconi anemia, Science, 297 (5581), 606-9

Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, Lane WS, Kastan MB, D’Andrea AD (2002) Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways, Cell, 109 (4), 459-72

Taniguchi T, Dandrea AD (2002) Molecular pathogenesis of fanconi anemia (review), International Journal of Hematology, 75 (2), 123-8

 

2001

Siddique MA, Nakanishi K, Taniguchi T, Grompe M, D’Andrea AD (2001) Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells, Experimental Hematology, 29 (12), 1448-55

Timmers C, Taniguchi T, Hejna J, Reifsteck C, Lucas L, Bruun D, Thayer M, Cox B, Olson S, D’Andrea AD, Moses R, Grompe M (2001) Positional cloning of a novel Fanconi anemia gene, FANCD2, Molecular Cell, 7 (2), 241-8

Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D’Andrea AD (2001) Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway, Molecular Cell, 7 (2), 249-62

 

1999

Taniguchi T, Chikatsu N, Takahashi S, Fujita A, Uchimaru K, Asano S, Fujita T, Motokura T (1999) Expression of p16INK4A and p14ARF in hematological malignancies, Leukemia, 13 (11), 1760-9

Ishida F, Kitano K, Ichikawa N, Ito T, Kohara Y, Taniguchi T, Motokura T, Kiyosawa K (1999) Hairy cell leukemia with translocation (11;20)(q13;q11) and overexpression of cyclin D1, Leukemia Research, 23 (8), 763-5

Taniguchi T, Endo H, Chikatsu N, Uchimaru K, Asano S, Fujita T, Nakahata T, Motokura T (1999) Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis, Blood, 93 (12), 4167-78

Yufu Y, Goto T, Choi I, Uike N, Kozuru M, Ohshima K, Taniguchi T, Motokura T, Yatabe Y, Nakamura S (1999) A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation, Cancer, 85 (8), 1750-7

 

1998

Uchimaru K, Taniguchi T, Yoshikawa M, Fujinuma H, Fujita T, Motokura T (1998) Growth arrest associated with 12-o-tetradecanoylphorbol-13-acetate-induced hematopoietic differentiation with a defective retinoblastoma tumor suppressor-mediated pathway, Leukemia Research, 22 (5), 413-20

Taniguchi T, Fujita A, Takahashi S, Uchimaru K, Yoshikawa M, Asano S, Fujita T, Motokura T (1998) Cyclin D1 overexpression detected by a simple competitive reverse transcription-polymerase chain reaction assay for lymphoid malignancies, Japanese Journal of Cancer Research : Gann, 89 (2), 159-66

 

1997

Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T, Motokura T (1997) Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma, Blood, 89 (3), 965-74

 

1995

Motokura T, Kobayashi Y, Fujita A, Nakamura Y, Taniguchi T, Uchimaru K, Asano S (1995) Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma, Leukemia & Lymphoma, 16 (3-4), 355-62